Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 50 (RPL23AP50)
- Target
- RPL23AP50
- Molecular classification
- Other (Pseudogene)
01
Overview
RPL23AP50 (ribosomal protein L23a pseudogene 50) is a processed pseudogene corresponding to the ribosomal protein L23a gene family. It is located in the human genome but does not encode a functional protein. Pseudogenes such as RPL23AP50 typically arise from gene duplication or retrotransposition and persist as non-functional genomic elements. While some pseudogenes are transcribed and may possess regulatory roles, there are no published reports of protein-coding capacity or direct involvement of RPL23AP50 in human disease or drug response. The molecule is not considered a therapeutic target, nor is it an established biomarker, and its standard classification is as a pseudogene within the ribosomal protein L23a gene family.
- Other names
- RPL23A_20_731RPL23AP50
02
Mechanism of action
Null. No known mechanisms of drug action, as this is not a direct target.
03
Biological functions
Null. Pseudogenes are typically nonfunctional; there are no reported direct biological functions outside of potential non-coding RNA regulatory activity, which remains speculative for RPL23AP50.
04
Disease associations
Null. No direct disease association; however, some ribosomal protein pseudogenes have been studied for differential expression in diseases (these mostly refer to other family members such as RPL23AP53).
05
Safety considerations
Null. There are no safety concerns directly associated with targeting RPL23AP50.
06
Interacting drugs
Null. No drugs are known to interact with RPL23AP50.
07
Biomarkers
Null. RPL23AP50 is not recognized as a clinical biomarker.
Beyond the preview
Go deeper on Ribosomal protein L23a pseudogene 50 (RPL23AP50).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 50 (RPL23AP50).